Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 9, 2024 – Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial re ...

Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Conference Call February 29, 2024 9:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Chris Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Caroline Pocher - Wedbush Securities Joon Lee - Truist Securities Tom Shrader - BTIG Operator Welcome to Verona Pharma's Fourth Quarter and Full Year Qu ...

March 2024 Ensifentrine is an investigational drug and has not been approved by the FDA (or any other regulatory authority). Nasdaq: VRNA | www.veronapharma.com Developing innovative therapies for the treatment of respiratory diseases Forward-looking statements This presentation contains "forward‐looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 Verona Pharma plc (Exact name of Registrant as specified in its Charter) United Kingdom 98-1489389 (State or other ...

Financial Performance - The net loss for Q4 2023 was $14.1 million, compared to a net loss of $10.5 million in Q4 2022[10][15]. - Revenue for Q4 2023 was $0, unchanged from Q4 2022, while total revenue for the year was also $0, consistent with the previous year[21]. - Gross profit for Q4 2023 was $0, maintaining the same level as Q4 2022, with a gross profit of $112,000 for the year[21]. - The net loss for Q4 2023 was $14,132,000, compared to a net loss of $10,451,000 in Q4 2022, with a total net loss of $54,369,000 for the year versus $68,701,000 in 2022[21]. - Loss per ordinary share for Q4 2023 was $0.02, consistent with Q4 2022, while the annual loss per share was $0.09 compared to $0.13 in 2022[21]. Research and Development - R&D expenses for the fourth quarter of 2023 were $4.1 million, down from $6.8 million in Q4 2022, primarily due to reduced clinical trial costs[10][11]. - Full-year R&D expenses for 2023 totaled $17.2 million, significantly down from $49.3 million in 2022, reflecting the completion of the Phase 3 ENHANCE program[10][15]. - The company plans to submit an IND for a fixed-dose combination formulation of ensifentrine and glycopyrrolate in the second half of 2024[10][12]. Selling, General and Administrative Expenses - SG&A expenses for Q4 2023 were $15.0 million, up from $8.3 million in Q4 2022, driven by increased personnel and commercialization preparation costs[10][15]. - Full-year SG&A expenses for 2023 were $50.4 million, an increase from $26.6 million in 2022, largely due to costs associated with building commercial infrastructure[10][15]. - Selling, general and administrative expenses increased to $14,972,000 in Q4 2023 from $8,323,000 in Q4 2022, with total expenses for the year rising to $50,353,000 from $26,579,000[21]. Cash and Assets - Cash and cash equivalents at December 31, 2023, were $271.8 million, an increase from $227.8 million at the end of 2022[10]. - Cash and cash equivalents increased to $271,772,000 in Q4 2023 from $227,827,000 in Q4 2022[21]. - Total assets rose to $308,124,000 in Q4 2023, up from $259,468,000 in Q4 2022[21]. - Shareholders' equity increased to $249,283,000 in Q4 2023 from $230,466,000 in Q4 2022[21]. Debt Financing and Future Plans - The company completed a $400 million debt financing facility in December 2023 to support commercialization and pipeline expansion[5][10]. - The FDA has assigned a PDUFA target action date of June 26, 2024, for the NDA of ensifentrine, which is aimed at treating COPD[10]. - The company expects to launch ensifentrine in the US market in the second half of 2024, pending FDA approval[10][7]. - The weighted average shares outstanding for Q4 2023 was 642,139,211, compared to 604,204,929 in Q4 2022[21].

Verona Pharma plc (NASDAQ:VRNA) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hahn - CFO Dr. Kathy Rickard - Chief Medical Officer Chris Martin - SVP, Commercial Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Andreas Argyrides - Wedbush Securities Tom Shrader - BTIG Dipesh Patel - H.C. Wainwright Operator Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 Verona Pharma plc (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of i ...

Verona Pharma plc. (NASDAQ:VRNA) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy Rickard - Chief Medical Officer Christopher Martin - Senior Vice President of Commercial Conference Call Participants Andreas Argyrides - Wedbush Andrew Tsai - Jefferies Edward Nash - Canaccord Genuity Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C. Wainwright Operator Welcome to Verona Pharma Second Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 3 More London Riverside London SE1 2RE United Kingdom Not Applicable (Address of principal executive offices) ( ...

Verona Pharma plc (NASDAQ:VRNA) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Officer Christopher Martin - Senior Vice President Commercial Conference Call Participants Andreas Argyrides - Wedbush David Risinger - SVB Securities Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C. Wainwright Joon Lee - Truist Securities Operator Good morning. Welcome to ...